Sartore-Bianchi, Andrea <br/><br/>
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2007 
 - 5942-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-0536  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Cell Line, Tumor<br/>Cell Survival<br/>Cell Transformation, Neoplastic<br/>Enzyme Inhibitors--pharmacology<br/>Humans<br/>Male<br/>Mesothelioma--drug therapy<br/>Mice<br/>Mice, Nude<br/>NF-kappa B--metabolism<br/>Nitriles--pharmacology<br/>Proteasome Inhibitors<br/>Pyrazines--pharmacology<br/>Sulfones--pharmacology<br/>Tumor Necrosis Factor-alpha--metabolism